alopecia

CRTh2 antagonist 2 is a selective and potent CRTH2 antagonist, IC50≤10 nM. CRTh2 antagonist 2 can be used to study the direction of androgenic alopecia.

GLF (H-Gly-Leu-Phe-OH), a tripeptide isolated from α-lactalbumin with immunostimulatory properties, prevents alopecia, epidermal thickening, and adipocyte layer thinning induced by the anticancer agent Etoposide [1].

Diphenylcyclopropenone (DPCP) is a topical drug used to treat alopecia areata, alopecia totalis, and refractory warts. Diphencyprone acts as a local stimulator that triggers an immune response against the action of autoreactive cells.

Alpha-Estradiol (Epiestradiol) is an estrogen that inhibits 5alpha-reductase and has potential in the study of androgenetic alopecia.

TP0427736 hydrochloride can be used in the androgenic alopecia (AGA) research. TP0427736 hydrochloride inhibits the phosphorylation of Smad2/3 in A549 cells induced by TGF-β1 with an IC50 value of 8.68 nM. TP0427736 hydrochloride is a potent ALK5 kinase inhibitor with an IC50 value of 2.72 nM which is 300-fold more potent than inhibitory effect against ALK3 of 836 nM [1].

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

5α-reductase-IN-1 is a potent inhibitor of the enzyme 5α-reductase. This compound is primarily employed in research studies to investigate its potential efficacy in treating patterned alopecia. It is commonly used in combination with minoxidil, a well-known treatment for hair loss.

Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC 50 of 4.2 nM for type II 5α-reductase. The affinity of Finasteride acetate for type II 5α-reductase enzyme was approximately 100-fold higher than that for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia [1] [2] [3].

Apoptosis Inhibitor was a novel inhibitor of programmed cell death associate with caspase-3 inhibition.

5-Androstenetriol, a steroid and active metabolite of dehydroepiandrosterone (DHEA), demonstrates significant therapeutic effects. Administered at 0.75 mg/25 g body weight, it mitigates radiation-induced mortality and facilitates hematopoietic recovery from surviving stem cells in mice. Moreover, a dosage of 40 mg/kg enhances survival rates in rats subjected to surgical trauma-induced sepsis. Additionally, elevated urinary levels of 5-androstenetriol are observed in women suffering from androgenic alopecia.

Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM. Wnt pathway activator 1 is a potent Wnt activator for the treatment of androgenetic alopecia (AGA).

PF 00277343, a thyroid receptor agonist, is used for the treatment of androgenetic alopecia.

Lapisteride (CS-891) a steroidal 5α-reductase inhibitor is used to treat benign prostatic hyperplasia (BPH) and androgenetic alopecia and may be effective in preventing or treating AGA .

(Rac)-PF-998425 is a potent, selective, nonsteroidal antagonist of the androgen receptor (AR), with IC50 values of 26 nM and 90 nM in AR binding and cellular assays, respectively. This compound shows promise for investigating androgenetic alopecia.

GW 9578 is a selective and potent PPARα agonist with potent lipid-lowering activity for the study of psoriasis, arthritis, alopecia, asthma and type I diabetes.